GFAP and nervous system disorder: The measurement of GFAP as a blood‐based biomarker was facilitated by the advent of ultra‐sensitive technologies to detect proteins at biologically relevant concentrations, resulting so far in a large number of studies examining levels of GFAP in clinical samples from patients with different neurological diseases (Abdelhak et al., 2022; Ishiki et al., 2016; Oeckl et al., 2022; Teunissen et al., 2022).